Researchers and pharmaceutical companies now have a new tool at their disposal to help them make important scientific breakthroughs. At the beginning of March, MassMatrix, provider of protein bioinformatic solutions, announced it had developed an innovative approach that delivers deeper and more accurate insights into proteomic data while streamlining the user experience to reduce the time it takes to convert raw data to actionable intel for research organizations and pharmaceutical companies.
“Genomic analysis helps explain if someone has a predisposition to certain diseases, but proteins are a necessary component for analyzing whether that predisposition has started to express itself in the body,” said Hall Johnson, co-founder and CEO of MassMatrix. “Deeper and more accurate analytics are critical for today’s researchers and pharmaceutical companies looking for biomarkers and developing complex bio drugs based on large protein molecules.”
MassMatrix’s advanced algorithms were developed in the cancer research laboratory of Dr. Michael A. Freitas at Ohio State University. These algorithms enhance protein characterization and peptide mapping workflows by reducing false discovery rates. Leveraging these advanced algorithms, MassMatrix’s new approach offers an intuitive interface, better visualization and easier reporting, and ultimately saves organizations time and money, while also expediting advances in science.
“Janssen is dedicated to solving today’s most important unmet medical needs,” said Darryl Davis, associate director at Janssen, Pharmaceutical Companies of Johnson and Johnson. “So, new innovations to MassMatrix’s proven high-resolution data supporting analytics are very exciting and an important advancement for our industry.” MassMatrix’s analytical mapping platform is being used by hundreds of scientists around the world with new innovations available this summer.
For more information, visit http://www.massmatrix.bio